Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-10-18

Clinical Trial Update: Belatacept in Liver Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 trial of belatacept for immunosuppression in liver transplant recipients was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nulojix (belatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Immunosuppression in Solid Organ Transplant | Phase 2 | Status: TERMINATED | Results posted: 2012-10-18